Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of methotrexate, pegfilgrastim, oxaliplatin, paclitaxel, and actinomycin D in relapsed poor-prognosis germ cell tumour
2010-022795-31Phase 2Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Jun 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, pegfilgrastim, oxaliplatin, paclitaxel and actinomycin D in germ cell tumor (GCT), sponsored by Barts Health NHS Trust. Primary endpoint: Complete response and negative marker partial response. Started Jun 2011; status: completed.
02
Drugs
methotrexatepegfilgrastimoxaliplatinpaclitaxelactinomycin D
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2010-022795-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022795-31.